ORM-5029

ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2) -targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab (HY-P9912) . ORM-5029 exhibits robust efficacy across 14 HER2-positive breast cancer cell lines, with IC50 values ranging from 0.3 to 14.4 nM.ORM-5029 demonstrates anti-tumor activity in the BT474 xenograft model. ORM-5029 can be used for study of breast cancer[1][2][3].

Product Specifications

UNSPSC

12352211

Target

Antibody-Drug Conjugates (ADCs)

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/orm-5029.html

Purity

99.60

Smiles

[R]O[M5029]

References & Citations

[1]Sara A. Hurvitz, et al. A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Journal of Clinical Oncology. Volume 41, Number 16_suppl. May 31, 2023.|[2]James Palacino, et al. ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer.|[3]Tao Y, et al. Molecular glue meets antibody: next-generation antibody-drug conjugates. Trends Pharmacol Sci. 2025 Jun;46 (6) :520-534.